The Biology of Healing

Understanding how the body protects, repairs, and restores itself—one biological system at a time.

Lesson 5

The Conversation Between THC and the Cell

In the last lesson, we explored one of the strangest and most important abilities of healthy biology: sometimes the healthiest thing a cell can do is die. Apoptosis—programmed cell death—is one of the mechanisms your body uses to remove cells that have become damaged, unnecessary, or potentially dangerous. Cancer complicates that process because malignant cells can acquire ways to resist the signals that would normally tell them to stop dividing or die.

That left us with a fascinating question. If laboratory research shows that THC can push certain cancer cells toward apoptosis, how does a molecule from a cannabis plant possibly have that conversation with a human cell?

THC doesn’t carry a tiny hammer. It doesn’t swim through the bloodstream looking for suspicious characters. And despite what a few cannabis memes might have you believe, THC isn’t a microscopic bounty hunter kicking down the door of every mutated cell it finds.

The reality is considerably more interesting.

THC sends signals. And cells answer.

Long before humans ever cultivated cannabis, our cells already possessed machinery capable of responding to cannabinoid signals. As we learned earlier in this series, the body contains an endocannabinoid system made up of signaling molecules, enzymes, and receptors distributed throughout the brain, immune system, organs, and tissues. Two of its best-known receptors are CB1 and CB2, and THC can bind to and activate both.

Think of a receptor as a biological lock. A signaling molecule interacts with it, the receptor changes its activity, and that message begins traveling through the cell. One signal becomes another, which becomes another, until something that happened at the cell membrane can ultimately influence events deep inside the cell.

That’s cellular communication.

And in certain experimental cancer models, that conversation can become remarkably consequential.

One of the best-studied examples comes from glioma research. In these models, cannabinoid-receptor activation by THC has been associated with increased levels of ceramide, a lipid signaling molecule involved in cellular stress, growth regulation, autophagy, and cell death. As that signaling develops, the cell can experience stress within its endoplasmic reticulum and begin changing pathways responsible for growth and survival. Researchers have identified downstream effects involving Akt and mTOR—important cellular survival and growth pathways—followed by autophagy and ultimately apoptotic cell death. (pmc.ncbi.nlm.nih.gov)

You don’t need to memorize the alphabet soup of proteins involved.

What matters is the sequence.

THC encounters a receptor. The receptor changes cellular signaling. Cellular signaling changes what the cell does next.

That’s the story.

Autophagy adds another fascinating layer. Cells normally use autophagy to break down and recycle damaged proteins and cellular components. It’s essentially biological housekeeping. But depending on the circumstances, autophagy can help a cell survive stress or participate in a sequence that ends in death. In important THC glioma experiments, autophagy occurred before apoptosis, and interfering with the autophagy machinery reduced THC-induced cell death. (pmc.ncbi.nlm.nih.gov)

In other words, THC wasn’t simply poisoning the cell.

It was influencing signaling that caused the cell’s own machinery to participate in what happened next.

That distinction is enormous.

It also raises an obvious question. If THC can influence these pathways, why doesn’t every cell exposed to THC die?

Because biology isn’t that simple.

Different tissues express different receptors. Different cancers carry different mutations. Receptor density varies. Metabolism varies. The tumor microenvironment varies. Even two people diagnosed with the same type of cancer can have tumors with very different molecular characteristics.

And intriguingly, some preclinical glioma research has found cannabinoid-induced apoptosis in malignant cells while normal glial cells were comparatively protected in those experimental systems. The National Cancer Institute summarizes laboratory and animal research involving cannabinoid-induced apoptosis and tumor responses while also making clear that these findings have not established cannabis as a proven cancer treatment in humans. (cancer.gov)

That distinction matters.

The laboratory evidence gives us mechanisms worth investigating. It doesn’t give us permission to pretend every unanswered clinical question has already been settled.

But neither should incomplete human evidence be used to pretend the underlying biology doesn’t exist.

Both things can be true.

That’s where I think the cannabis conversation has gone wrong for decades. One side wants cannabis to be a miracle. The other wants it to be irrelevant. Biology isn’t particularly interested in either position.

Cancer isn’t one disease, either. Glioblastoma isn’t pancreatic cancer. Pancreatic cancer isn’t melanoma. Melanoma isn’t breast cancer. Some experimental tumors respond through CB1 signaling, others involve CB2, and CBD often works through mechanisms that extend beyond either receptor. The cannabinoid, dose, ratio, timing, tumor biology, receptor expression, and surrounding cellular environment can all change the response.

This is why cannabis extracts interest me.

When most people hear “THC,” they think about getting high.

I think about signaling.

THC interests me because of its interaction with cannabinoid receptors and the downstream pathways researchers have observed. CBD interests me because some of its biological actions overlap with THC while others are remarkably different. Whole-plant extracts raise additional questions because cannabis contains numerous biologically active compounds whose interactions remain an active area of research.

For people facing serious health problems, I think they deserve to know that research exists. Not exaggerated. Not wrapped in miracle language. And not dismissed with, “Cannabis helps cancer patients with nausea.”

That’s part of the story.

It isn’t the whole story.

For most of the twentieth century, society argued about whether people should be allowed to use cannabis while biology quietly continued doing what biology does. Receptors bound molecules. Enzymes worked. Immune cells communicated. Survival pathways switched on and off. None of it cared about politics, stigma, prohibition, or popularity.

Biology doesn’t negotiate. It responds to signals.

And once we understand that, the cannabis question becomes much more sophisticated than asking whether cannabis is “good” or “bad.”

The better question is:

What signal are we sending, to which cell, through which pathway, at what concentration—and what does that cell do with the message?

Now we’re getting somewhere.

The Biology

THC acts at CB1 and CB2 cannabinoid receptors, and in several preclinical cancer models cannabinoid signaling has influenced pathways involved in proliferation, survival, autophagy, angiogenesis, and apoptosis. One extensively studied pathway in glioma models involves cannabinoid-receptor activation, ceramide signaling, cellular stress, suppression of Akt/mTOR survival signaling, autophagy, and eventually apoptotic cell death. These responses vary according to cancer type, cannabinoid concentration, receptor expression, molecular characteristics, and experimental conditions. (pmc.ncbi.nlm.nih.gov)

The mechanisms are biologically significant, but preclinical mechanisms are not the same thing as demonstrated clinical effectiveness. Human research on cannabinoids as cancer-directed treatment remains limited, which is why cannabinoid use during cancer treatment should be coordinated with qualified clinicians, particularly when other medications are involved. (cancer.gov)